loading page

EUFOREA/EPOS2020 Statement on the Clinical Considerations for CRSwNP Care
  • +30
  • Wytske Fokkens,
  • Peter Hellings,
  • Isam Alobid,
  • Wilma Anselmo-Lima,
  • Manuel Bernal-Sprekelsen,
  • Leif Bjermer,
  • Lisa Caulley,
  • Adam Chaker,
  • Jiannis Constantinidis,
  • Diego M. Conti,
  • De Corso E.,
  • Martin Desrosiers,
  • Zuzana Diamant,
  • Philippe Gevaert,
  • Han Han. J,
  • Enrico Heffler,
  • Clair Hopkins,
  • Basile Landis,
  • Olga Lourenço,
  • Valerie Lund,
  • Amber Luong,
  • Joaquim Mullol,
  • Anju Peters,
  • Carl Philpott,
  • Sietze Reitsma,
  • Dermot Ryan,
  • Glenis Scadding,
  • Brent Senior,
  • Peter Tomazic,
  • Elina Toskala,
  • Thibaut van Zele,
  • An-Sofie Viskens,
  • Martin Wagenmann
Wytske Fokkens
Amsterdam Universitair Medische Centra

Corresponding Author:w.j.fokkens@amsterdamumc.nl

Author Profile
Peter Hellings
Katholieke Universiteit Leuven
Author Profile
Isam Alobid
Hospital Clinic de Barcelona
Author Profile
Wilma Anselmo-Lima
Universidade de Sao Paulo - Campus de Ribeirao Preto
Author Profile
Manuel Bernal-Sprekelsen
IQVIA Espana Barcelona
Author Profile
Leif Bjermer
Lunds universitet Lungmedicin och Allergologi
Author Profile
Lisa Caulley
Canada Gazette
Author Profile
Adam Chaker
Klinikum rechts der Isar der Technischen Universitat Munchen
Author Profile
Jiannis Constantinidis
Aristoteleio Panepistemio Thessalonikes Schole Thetikon Epistemon
Author Profile
Diego M. Conti
Katholieke Universiteit Leuven Onderzoeksgroep Experimentele Oto-rino-laryngologie
Author Profile
De Corso E.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Author Profile
Martin Desrosiers
Universite de Montreal
Author Profile
Zuzana Diamant
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
Author Profile
Philippe Gevaert
University of Pennsylvania Department of Otorhinolaryngology
Author Profile
Han Han. J
Virginia High School
Author Profile
Enrico Heffler
IRCCS Humanitas Research Hospital Department of Gastroenterology
Author Profile
Clair Hopkins
Guy's and St Thomas' NHS Foundation Trust Ear Nose and Throat Head and Neck Service
Author Profile
Basile Landis
UH Geneva Medical Center
Author Profile
Olga Lourenço
Universidade da Beira Interior Faculdade de Ciencias da Saude
Author Profile
Valerie Lund
Royal National ENT and Eastman Dental Hospitals
Author Profile
Amber Luong
The University of Texas Health Science Center at Houston Department of Anesthesiology
Author Profile
Joaquim Mullol
Hospital Clinic de Barcelona Instituto Clinic de Neurociencias
Author Profile
Anju Peters
Northwestern University Feinberg School of Medicine Department of Pharmacology
Author Profile
Carl Philpott
University of East Anglia Norwich Medical School
Author Profile
Sietze Reitsma
Amsterdam Universitair Medische Centra
Author Profile
Dermot Ryan
The University of Edinburgh Division of Health Sciences
Author Profile
Glenis Scadding
University College London Division of Infection and Immunity
Author Profile
Brent Senior
Norfolk and Norwich University Hospitals Eye Department
Author Profile
Peter Tomazic
Medizinische Universitat Graz
Author Profile
Elina Toskala
Thomas Jefferson University
Author Profile
Thibaut van Zele
University of Pennsylvania Department of Otorhinolaryngology
Author Profile
An-Sofie Viskens
Katholieke Universiteit Leuven
Author Profile
Martin Wagenmann
Universitatsklinikum Dusseldorf
Author Profile

Abstract

Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals, and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment, and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications, and considerations that are of importance to the patient, the physician, and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.
24 Oct 2023Submitted to Allergy
24 Oct 2023Submission Checks Completed
24 Oct 2023Assigned to Editor
24 Oct 2023Review(s) Completed, Editorial Evaluation Pending
27 Oct 2023Reviewer(s) Assigned
13 Nov 2023Editorial Decision: Revise Minor
19 Nov 20231st Revision Received
19 Nov 2023Review(s) Completed, Editorial Evaluation Pending
19 Nov 2023Submission Checks Completed
19 Nov 2023Assigned to Editor
19 Nov 2023Reviewer(s) Assigned